SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below key support levels are dominating discussion, with traders pointing to leveraged-long liquidations and broader risk-off pressure across crypto and tech as possible contributors. The community is split between warnings of further downside and calls to buy an oversold dip or watch for support.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas reiterated that topline results from its Phase 3 REGAL trial of GPS in AML are expected in November after the trial reached its required event milestone, drawing attention to the pending binary readout. Traders are broadly excited about the prospect of positive data and a short squeeze, while speculation about a leak or buyout remains unconfirmed and skeptics stress that results have not been released and the trial outcome is uncertain.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about work interruptions and concern that the prolonged disruption could damage trust or pressure the stock. Some traders speculated about a cyberattack, but the cause was not confirmed, and others questioned why shares held relatively steady.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline toward the $1 support level amid a broader crypto selloff is dominating discussion, with traders pointing to Bitcoin weakness, inflation and rate concerns, and liquidations. Bears warn of further downside and question Ripples ability to provide catalysts, while some holders view the drop as a buying opportunity and continue accumulating.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Weakness in Ethereum and broader crypto-linked stocks is weighing on BitMine, while traders also criticize its underperformance and question managements spending, transparency, and buybacks. Some see the stocks discount to its crypto holdings as a buying opportunity, but bearish posts argue falling ETH prices can overwhelm any support from repurchases.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure as Bitcoin and broader crypto markets sell off, with traders highlighting COINs repeated new lows and weak performance even when Bitcoin stabilizes. Bearish calls dominate, though some see the decline as oversold and are buying the dip.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Year-ender 2025 view on Indian pharma achievements

2025 felt like a quiet reset for Indian pharma. Exports and policy support remained important, but the more meaningful shift was in what people focused on inside companies and hospitals, said Saransh Chaudhary, president, global critical care, Venus Remedies and chief executive, Venus Medicine Research Center in a personal view on the Indian pharmaceutical sector.

Bad drugs or no drugs: Cancer patients face scary reality tied to foreign supply chain

… shelves of pharmacies rooted in the production of drugs in India … U.S., supplied by Intas Pharmaceuticals , failed one out of … us inside the oncology pharmacy where the drugs that save his … broken system. -- Intas Pharmaceuticals and Venus Remedies did not …

Ixigo And Venus Remedies Show Long-term Upside Potential: SEBI RA Gunjan Kumar 

Equity

The analyst eyes breakout opportunities in these two stocks, driven by their technical strength and growing institutional interest.

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

… or Sanofi , while one brand, Huminsulin by US-based pharma giant Eli Lilly , … care) of research-driven pharma company Venus Remedies. Innovative … case of small molecule drugs —have now hit the … “The entry of multiple pharmaceutical companies into this space …

Medivirs CEO to BioStock: I am proud to see our research contribute to a global solution

Antibiotic resistance is a growing global crisis, increasing the urgency for effective treatments. While Medivir now focuses on cancer therapies, it has a legacy in antimicrobial research. This was highlighted by Infex Therapeutics licensing agreement with Venus Remedies Ltd for the development of MET-X in India a compound developed from a research program that Medivir outlicensed in 2017. We reached out to Medivirs CEO Jens Lindberg for a comment. Read the interview with Jens Lindberg at biostock.se: https://www.biostock.se/en/2025/03/medivirs-ceo-i-am-proud-to-see-our-research-

India, EU to renew FTA negotiations

India and the European Union will this week take stock of their negotiations for an ambitious free trade deal and broadly firm up a new strategic agenda. Venus Remedies inks pact with UK firm New Delhi: Venus Remedies said it has joined hands with UK-based Infex Therapeutics for the development of MET-X, an inhibitor, to […]

Infex partners with Venus Remedies to develop MET-X in India

https://www.investing.com/news/company-news/infex-partners-with-venus-remedies-to-develop-metx-in-india-93CH-3888284

Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. Its products include analgesic, analgesic and antipyretic, anti diabetic, antibiotic, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizer, hormone, iron supplement, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. The company was founded by Pawan Chaudhary on September 15, 1989 and is headquartered in Panchkula, India.

Venus Remedies Ltd.

Neutral Sentiment

SEBI-registered analyst <a href="https://stocktwits.com/STOCKCEPE">Gunjan Kumar</a> has flagged Ixigo and Venus Remedies as stocks with potential long-term growth.IxigoKumar noted that Ixigo is nearly debt-free and has seen increased investment from domestic institutional investors (DII) in the past quarter, signaling growing investor confidence.<stembedurl>https://stocktwits.com/STOCKCEPE/message/617962420</stembedurl>The analyst said the strong demand from Tier II and III cities, where Ixigo enjoys a 94% penetration rate, is fueling the company’s growth.The company is now ramping up investment in hotel bookings to boost revenue, inspired by the success of its competitors.With India’s travel market projected to reach $48 billion by 2027, supported by rising incomes and improved infrastructure, Ixigo is well-positioned for sustained growth, according to Kumar.Technically, the stock recently broke resistance, closing above ₹185 for the first time. Kumar suggests watching for a move above ₹192, with support at ₹169.On the financial front, it has reported record-high revenue and over 70% year-on-year sales growth since its IPO.Venus RemediesVenus Remedies has an attractive valuation, according to Kumar. The company exports to over 70 countries and operates in a sector poised for growth.<stembedurl>https://stocktwits.com/symbol/VENUSREM.NSE</stembedurl>India’s pharmaceutical industry is expected to reach $65 billion by 2024, growing at 10–12% annually, driven mainly by demand for generic drugs.Fundamentally, Venus Remedies is almost debt-free and recently posted its highest net profit in the last 13 quarters, with revenue figures in line with the same quarter the previous year.The analyst said that foreign institutional investors (FIIs) have steadily increased their stakes over the past four quarters, signaling growing confidence in the company’s long-term prospects.From a technical perspective, the stock has broken out of a multi-year resistance zone and successfully retested it.The analyst suggested watching for ₹475 on the upside, with support at ₹424 on a closing basis.For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo credit should read INDRANIL MUKHERJEE/AFP via Getty Images)

Current Price	1,470.10
Prev Close	1,437.00
Open	1,440.00
Dividend Yield	1.21%
50-Day Moving Average	1,569.40
Beta	N/A
Avg. Volume	40,227.68
PE Ratio	15.87

52-Week High	2,044.30
52-Week Low	550.00
Market Capitalization	19.17B
EPS (Annual)	76.90
Price to Book	2.74
Revenue Per Employee	5.02M

Feed

News

Sentiment

Fundamentals

Info

VENUSREM.NSE Fundamentals